Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.04) by 2946.51 percent. This is a 76.18 percent increase over losses of $(5.50) per share from the same period last year.